A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

• Status: Completed
• Trial end date: 2011-12-01

Summary

Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.

• Phase: Phase 3

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Treatments: Androgens; Leuprolide